{"id":291,"date":"2026-11-19T02:03:26","date_gmt":"2026-11-19T02:03:26","guid":{"rendered":"https:\/\/astinovabiolabs.com\/blog\/?p=291"},"modified":"2026-11-19T02:03:26","modified_gmt":"2026-11-19T02:03:26","slug":"rmc-0708-kras-q61h-tri-complex-dossier","status":"publish","type":"post","link":"https:\/\/astinovabiolabs.com\/blog\/rmc-0708-kras-q61h-tri-complex-dossier\/","title":{"rendered":"RMC-0708: An Oral, Bis-Macrocyclic, RAS(ON) Q61H-Selective Tri-Complex Inhibitor \u2014 Drug\/Modality\/Target Intelligence Dossier"},"content":{"rendered":"\n<h2 class=\"wp-block-heading\">The problem: the Q61 codon RAS, left behind<\/h2>\n\n\n\n<p>Mutant-selective RAS drugs have, so far, been a <strong>G12 story<\/strong> \u2014 sotorasib, adagrasib, and the newer G12D and pan-KRAS agents. Patients whose tumors are driven by a <strong>Q61 codon<\/strong> mutation have been left out. <strong>KRAS Q61H<\/strong> alone accounts for ~7,500 new US cases a year, mostly in NSCLC, PDAC, and CRC. Pan-KRAS or RAS(ON)-multiselective agents will reach these patients, but they also hit <strong>wild-type RAS<\/strong> in healthy tissue. A genuinely <strong>Q61H-selective<\/strong> inhibitor would spare WT RAS \u2014 if you can find a noncovalent handle on the featureless surface of the active, GTP-bound protein.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">The modality: remodel a chaperone, then grab RAS<\/h2>\n\n\n\n<p>RMC-0708 is a <strong>tri-complex inhibitor (TCI)<\/strong>. It first binds the abundant cytosolic chaperone <strong>cyclophilin A (CYPA)<\/strong> and remodels its surface into a neomorphic interface with high affinity for <strong>RAS(ON) Q61H<\/strong>. The binary CYPA\u2013compound complex then clamps onto the GTP-bound mutant, forming a tri-complex that <strong>blocks effector (RAF) engagement<\/strong> and shuts down MAPK signaling. The scaffolds are beyond-rule-of-five (bRo5) macrocycles derived from <strong>sanglifehrin A<\/strong>, a natural CYPA binder.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">The strategy: a second macrocycle to catch Q61H<\/h2>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"2408\" height=\"1504\" src=\"https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/11\/rmc0708_design.png\" alt=\"\" class=\"wp-image-286\" srcset=\"https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/11\/rmc0708_design.png 2408w, https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/11\/rmc0708_design-300x187.png 300w, https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/11\/rmc0708_design-1024x640.png 1024w, https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/11\/rmc0708_design-768x480.png 768w, https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/11\/rmc0708_design-1536x959.png 1536w, https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/11\/rmc0708_design-2048x1279.png 2048w\" sizes=\"auto, (max-width: 2408px) 100vw, 2408px\" \/><figcaption class=\"wp-element-caption\">Design evolution from the linear lead to RMC-0708, showing the three pharmacophore edits. Original figure by Astinova Bio Labs (RDKit).<\/figcaption><\/figure>\n\n\n\n<p>Starting from the prior RAS(ON) inhibitor <strong>compound 1<\/strong> (only 2.5-fold Q61H\/WT), the crystal structure suggested room for one more contact. Closing a <strong>second macrocycle<\/strong> \u2014 a methylene bridge between the phenol and pyrrolidine \u2014 gave bis-macrocyclic <strong>compound 2<\/strong>, rigidifying the side chain so the <strong>amide carbonyl sits ~3 \u00c5 from the Q61H imidazole<\/strong> and accepts a hydrogen bond. Selectivity jumped past <strong>50-fold<\/strong>, MD confirmed pre-organization toward the bound pose, and \u2014 because the move also deleted the phenol H-bond donor \u2014 <strong>oral bioavailability climbed from &lt;2% to 33%<\/strong> with lower clearance.<\/p>\n\n\n\n<p>From there it was a three-edit march to the candidate:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n\n<li><strong>Amide cap:<\/strong> acetamide \u2192 \u03b1-methyl cyclopropyl \u2192 <em>gem<\/em>-difluoro, then a <strong>3-methyloxetane-3-carbonyl<\/strong> cap \u2014 tuning the Q61H H-bond and P-loop (G12) van der Waals contacts to single-digit\/sub-nM cellular potency and several-hundred-fold selectivity.<\/li>\n\n\n<li><strong>Basic amine:<\/strong> N-methyl piperazine \u2192 <strong>N-cyclopropyl piperidine<\/strong>, which restored <strong>Caco-2 permeability<\/strong>, cut efflux, and strengthened the <strong>CYPA cation\u2013\u03c0 contact with W121<\/strong> (KD1 down &gt;5-fold).<\/li>\n\n\n<li><strong>Indole N-substituent:<\/strong> N-ethyl \u2192 <strong>N-2,2,2-trifluoroethyl<\/strong>, lifting metabolic stability and oral exposure.<\/li>\n\n<\/ul>\n\n\n\n<p>The result \u2014 <strong>compound 31, RMC-0708<\/strong> (C\u2086\u2082H\u2087\u2089F\u2083N\u2088O\u2089, MW 1137).<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">The structural proof: caught on Q61H<\/h2>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1005\" height=\"836\" src=\"https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/11\/rmc0708_binding.png\" alt=\"\" class=\"wp-image-285\" srcset=\"https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/11\/rmc0708_binding.png 1005w, https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/11\/rmc0708_binding-300x250.png 300w, https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/11\/rmc0708_binding-768x639.png 768w\" sizes=\"auto, (max-width: 1005px) 100vw, 1005px\" \/><figcaption class=\"wp-element-caption\">RMC-0708 bound in the KRAS(ON) Q61H \u00b7 CypA tri-complex (PDB 36JS); His61 engages the macrocyclic amide. Rendered by Astinova Bio Labs (3Dmol.js).<\/figcaption><\/figure>\n\n\n\n<p>The co-crystal of the <strong>RMC-0708 \u00b7 KRAS(ON) Q61H \u00b7 CYPA<\/strong> tri-complex (<strong>PDB 36JS<\/strong>) shows the compound filling the composite pocket between CYPA and the RAS switch regions. On <strong>switch I<\/strong> it packs against Y32, P34, I36, and E37; on <strong>switch II<\/strong> the core engages <strong>Q61H<\/strong> through both a <strong>\u03c0\u2013\u03c0 stack and a hydrogen bond<\/strong>, with hydrophobic contacts to Y64\/M67; and the <strong>oxetane donates an H-bond to the backbone NH of G12<\/strong> in the P-loop. GMPPNP and Mg\u00b2\u207a mark the nucleotide site \u2014 this is the <em>active<\/em> state being drugged.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">The data: potent, selective, orally durable<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n\n<li><strong>Cellular selectivity.<\/strong> NanoBRET: complete disruption of <strong>KRAS Q61H\/RAF (EC\u2085\u2080 2.1 nM)<\/strong> but only partial WT\/RAF disruption up to 1 \u00b5M \u2014 a feature of the modality (the active species is capped by cellular CYPA, ~10 \u00b5M).<\/li>\n\n\n<li><strong>Antiproliferation.<\/strong> Median pEC\u2085\u2080 <strong>8.98<\/strong> across Q61H lines vs <strong>7.47<\/strong> for RAS WT \u2014 <strong>~32-fold<\/strong> cellular selectivity.<\/li>\n\n\n<li><strong>PK.<\/strong> Low clearance and oral exposure across mouse\/rat\/dog\/monkey (mouse %F 20, dog 46).<\/li>\n\n\n<li><strong>In vivo.<\/strong> A <strong>single oral dose<\/strong> drove deep, durable RAS-pathway suppression (tumor DUSP6) <strong>out to 72 h<\/strong>; daily dosing produced <strong>tumor regressions<\/strong> in T3M-4 (PDAC), HCC2108 (NSCLC), and CTG-1338 (CRC) xenografts, well tolerated.<\/li>\n\n\n<li><strong>Safety.<\/strong> No hERG\/Na\u1d651.5\/Ca\u1d651.2 inhibition (&gt;10 \u00b5M), clean SAFETYScreen47, and selective for KRAS Q61H over WT RAS and non-RAS GTPases.<\/li>\n\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">Why it matters<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n\n<li><strong>A mutant-selective answer for the Q61H population<\/strong> \u2014 sparing WT RAS by design, not by dose.<\/li>\n\n\n<li><strong>Macrocyclization as a precision tool.<\/strong> A second ring converted a 2.5-fold starting point into a &gt;200-fold-selective, orally bioavailable bRo5 molecule \u2014 the carbonyl placed by geometry, not luck.<\/li>\n\n\n<li><strong>The tri-complex platform, extended.<\/strong> RMC-0708 shows the CYPA-remodeling modality can be tuned to a specific Q61 variant with a solved co-crystal to prove the mechanism.<\/li>\n\n<\/ul>\n\n\n\n<p><strong>Reference:<\/strong> Thompson, S. K.; Yang, Y. C.; L\u00f3pez Qui\u00f1ones, A. J.; Chang, S.; McKinley, J. L.; Tomlinson, A. C. A.; Tooley, A. S.; Wei, X.; Flagella, M.; Buckl, A.; Gliedt, M. J.; Yin, J.; Liu, Y.; Chen, A.; Montgomery, D. C.; Marquez, A.; Eilerts, D. F.; Probst, J.; McNamara, A.; Shivakumar, D. M.; Wang, Zhican; Knox, J. E.; Wang, Zhengping; Gill, A. L.; Koltun, E. S. &#8220;Discovery of RMC-0708, an Oral, Bis-Macrocyclic, RAS(ON) Q61H-Selective, Noncovalent, Tri-Complex Inhibitor.&#8221; <em>J. Med. Chem.<\/em> <strong>2026<\/strong>, DOI: 10.1021\/acs.jmedchem.6c02019. Open access under CC-BY 4.0.<\/p>\n\n\n\n<p><em>All visuals are original to Astinova Bio Labs: the design\/SAR and structure panels drawn with RDKit\/Matplotlib; the tri-complex binding view rendered with 3Dmol.js from the deposited co-crystal PDB 36JS.<\/em><\/p>\n\n\n\n<p><em>Astinova Bio Labs designs and makes molecules like these \u2014 macrocyclization strategy, bRo5 property optimization, and structure-based binding analysis. <a href=\"https:\/\/astinovabiolabs.com\/\">Talk to us<\/a> about your target.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>How a second macrocycle turned a 2.5-fold starting point into RMC-0708 \u2014 an orally bioavailable, >200-fold KRAS Q61H-selective RAS(ON) tri-complex inhibitor, with the deposited co-crystal to prove it.<\/p>\n","protected":false},"author":1,"featured_media":284,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[26],"tags":[107,105,60,37,108,64,106],"class_list":["post-291","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-medicinal-chemistry","tag-cyclophilin-a","tag-kras-q61h","tag-macrocyclization","tag-oncology","tag-rason","tag-selectivity","tag-tri-complex-inhibitor"],"_links":{"self":[{"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/posts\/291","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/comments?post=291"}],"version-history":[{"count":1,"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/posts\/291\/revisions"}],"predecessor-version":[{"id":294,"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/posts\/291\/revisions\/294"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/media\/284"}],"wp:attachment":[{"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/media?parent=291"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/categories?post=291"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/tags?post=291"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}